Local cover image
Local cover image
Image from Google Jackets

Prevalence and Predictors of Virological Failure among Adults HIV Patients Receiving First Line ART in Northwestern Tanzania A Cross Sectional Study

By: Contributor(s): Material type: TextTextPublisher number: Phone: +255 28 298 3384 Fax: +255 28 298 3386 Email: vc@bugando.ac.tz Website: www.bugando.ac.tz Language: English Series: ; EC Microbiology Volume 15 Issue 9Publication details: Mwanza: Tanzania Catholic University of Health and Allied Sciences [CUHAS – Bugando] 2020/9/7 Description: Pages 683-90Online resources: Summary: Background: Prevalence of immunological failure has been shown to be high in some African countries. Few studies however have assessed the magnitude of virological failure in Tanzania. This study aimed at determining virological failure and its associated factors in north western Tanzania. Methods: A cross sectional study was conducted among HIV-infected patients who were receiving first line ART at Bugando medical centre. Virological loads were measured and socio-demographic and clinical information were collected for analysis. Patients with a single viral load of> 10,000 copies/ml were coded as having virological failure as per WHO definition and poor adherence level was defined as any adherence level of< 95%. Data analysis was done using STATA 11 to determine the proportion of patients with virological failure and its associated factors. Results: In total 274 patients were enrolled and, 43 (15.7%) met the criteria of virological failure. The odds of having virological failure were independently associated with baseline CD4 counts of< 200 cells/µl (AOR= 8.6 (1.7-42.1), p= 0.008), poor adherence (AOR= 15.4 (6.6-36.1), p< 0.0001) and Nevirapine based regimen (AOR= 4.1 (1.6-10.4), p= 0.003). Conclusion: Virological failure is prevalent among HIV patients on first line ART. Test and treat, adherence counseling and regular virological monitoring could optimize the virological outcome of HIV patients receiving first line ART in Tanzania and similar setting.
Item type: RESEARCH ARTICLES
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Collection Status Barcode
RESEARCH ARTICLES MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO NFIC -1 RA0586
Total holds: 0

Background: Prevalence of immunological failure has been shown to be high in some African countries. Few studies however have assessed the magnitude of virological failure in Tanzania. This study aimed at determining virological failure and its associated factors in north western Tanzania.

Methods: A cross sectional study was conducted among HIV-infected patients who were receiving first line ART at Bugando medical centre. Virological loads were measured and socio-demographic and clinical information were collected for analysis. Patients with a single viral load of> 10,000 copies/ml were coded as having virological failure as per WHO definition and poor adherence level was defined as any adherence level of< 95%. Data analysis was done using STATA 11 to determine the proportion of patients with virological failure and its associated factors.

Results: In total 274 patients were enrolled and, 43 (15.7%) met the criteria of virological failure. The odds of having virological failure were independently associated with baseline CD4 counts of< 200 cells/µl (AOR= 8.6 (1.7-42.1), p= 0.008), poor adherence (AOR= 15.4 (6.6-36.1), p< 0.0001) and Nevirapine based regimen (AOR= 4.1 (1.6-10.4), p= 0.003).

Conclusion: Virological failure is prevalent among HIV patients on first line ART. Test and treat, adherence counseling and regular virological monitoring could optimize the virological outcome of HIV patients receiving first line ART in Tanzania and similar setting.

There are no comments on this title.

to post a comment.

Click on an image to view it in the image viewer

Local cover image
Share
Catholic University of  Health and Allied Sciences - CUHAS
Directorate of ICT @ 2024